TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Study of N91115 to Evaluate Safety and Pharmacokinetics in Patients With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation
Brief Summary: This Phase 1b study in F508del-CFTR homozygous CF patients is being conducted to assess the safety of N91115 as the sole cystic fibrosis transmembrane conductance regulator (CFTR) modulator at doses near the expected therapeutic exposure level in preparation for Phase 2 studies of N91115 added to the CFTR modulator combination lumacaftor/ivacaftor when launched.


Options:
A: Arm Label: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-809, Drug: VX-770 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): LUM/IVA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VX-770; Assigned to Arm(s): LUM/IVA
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h
C: Arm Label: Group 1 - 50 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 2 - 100 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 3 - 200 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 4 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: N91115 | Intervention Type: DRUG; Name: N91115; Assigned to Arm(s): Group 1 - 50 mg, Group 2 - 100 mg, Group 3 - 200 mg, Group 4 - Placebo
D: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lifestyle Management of CKD in Obese Diabetic Patients
Brief Summary: The purpose of this randomized clinical trial is to evaluate the efficacy of 3 different technology-supported approaches to engaging 300 individuals with diabetes and concurrent chronic kidney disease in weight loss, dietary sodium restriction, and dietary restriction of inorganic phosphates when compared to usual care. Participants will be randomized to 1 of 4 groups, Usual Care (UC), Social Cognitive Theory-based Group Counseling (SCT), Mobile self-monitoring with tailored feedback and counseling (MONITORING), or a combination of SCT plus MONITORING conditions (COMBINED). Investigators will evaluate the intervention arms primarily in terms of weight reduction, urinary sodium excretion, and serum phosphorus and, secondarily in terms of physical activity, blood pressure, fasting lipids, medication requirements, and pulse wave velocity. Measurements will occur at baseline, 6, and 12 months. The statistical modeling of the baseline, 6 mos and 12 mos outcome variables will be based on logistic generalized linear mixed models (for binary outcomes) linear mixed models (for continuous outcomes), and random effects multinomial models (for outcomes with more than 2 levels, such as changes in medication management). In separate analyses of the intervention arm only, investigators will model self-monitoring adherence and examine possible associations between self-monitoring adherence and outcomes. The mediating effect of self-efficacy on the primary outcomes will be evaluated using structural equation models.


Options:
A: Arm Label: Sodium Reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Sodium Reduction | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sodium Reduction; Assigned to Arm(s): Sodium Reduction
B: Arm Label: Low Sodium Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Low Sodium Diet | Arm Label: Usual Diet; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Low Sodium Diet; Assigned to Arm(s): Low Sodium Diet
C: Arm Label: Usual Care (UC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Social Cognitive Theory (SCT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Social Cognitive Theory | Arm Label: Monitoring; Type: ACTIVE_COMPARATOR; Interventions: Other: Monitoring | Arm Label: Combined; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Social Cognitive Theory, Other: Monitoring | Intervention Type: BEHAVIORAL; Name: Social Cognitive Theory; Assigned to Arm(s): Combined, Social Cognitive Theory (SCT) | Intervention Type: OTHER; Name: Monitoring; Assigned to Arm(s): Combined, Monitoring
D: Arm Label: Low Salt Diet; Type: EXPERIMENTAL; Interventions: Other: Dietary salt reduction | Arm Label: Standard Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Dietary salt reduction; Assigned to Arm(s): Low Salt Diet

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction)
Brief Summary: Rationale: Severe, early-onset fetal growth restriction (FGR) due to placental insufficiency is associated with a high risk of perinatal morbidity with long-lasting sequelae and mortality. Placental insufficiency is the result of abnormal formation and function of the placenta (placentation) with inadequate remodelling of the maternal spiral (uteroplacental) arteries. There is currently no therapy available with demonstrated effectiveness. Evidence suggests Sildenafil citrate improves uteroplacental blood flow, growth, and meaningful outcomes.

Objective: To evaluate the effectiveness of sildenafil (versus placebo) in achieving healthy perinatal survival.

Study design: Multicenter nationwide randomized placebo-controlled clinical trial.

Study population: Women with a singleton pregnancy between 20 and 30 weeks with severe fetal growth restriction of likely placental origin, and with estimated significant likelihood of perinatal death.

Intervention: Sildenafil 25mg or placebo tablet orally three times daily. Main study parameters/endpoints: Perinatal healthy survival, i.e. survival without severe neonatal morbidity at term age.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Taking tablets three times daily. No additional ultrasounds, other than standard clinical protocol, one extra blood sample at inclusion. No risks anticipated, unexpected medication-associated risks can't be excluded on beforehand.


Options:
A: Arm Label: Sildenafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sildenafil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Sildenafil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Sildenafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sildenafil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Sildenafil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: L ARG | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: L ARG; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Wellness Program Implementation: School & Student Toolkits
Brief Summary: The project is designed to evaluate a participatory implementation model in HealthCorps (HC) high schools and to assess outcomes within and across school settings . The behavioral objectives from the 2010 Dietary Guidelines to address obesity in youth include: 1) decreasing sugary beverage intake; 2) increasing frequency of breakfast; 3) increasing vegetable and fruit intake to 2½ cups per day;4) decreasing frequency of fast food meals;5) becoming physically active (goal of 1 hour per day); and 6) reducing sedentary behavior time (\<2 hour day). The study is employing system dynamics modeling (SDM) to assess wellness programming options and to evaluate the program implementation within the context of diverse school ecologies. The RE-AIM evaluation metric (Reach, Effectiveness, Adoption, Implementation, and Maintenance) is used to guide SDM development and validation.

The Specific Aims are:

1. To use PAR (Participatory Action Research) methods to refine the school wellness program model and toolkit components that address institutional/community level program implementation barriers and individual level barriers to achieving healthy lifestyle recommendations.
2. To assess the effectiveness of program components using process evaluation techniques guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) model.
3. To evaluate implementation with system dynamics modeling to facilitate dissemination. The simulation analysis will apply the RE-AIM framework to address: Reach (participation rates), effectiveness (outcomes), adoption (acceptability), implementation (intervention fidelity), and maintenance (sustainability of lifestyle changes by students and programs by schools), in order to facilitate refining the toolkits and training program for dissemination to other school setting and diverse educational venues.


Options:
A: Arm Label: HC toolkit intervention students; Type: EXPERIMENTAL; Interventions: Behavioral: Toolkit Intervention | Arm Label: Comparison Schools; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Toolkit Intervention; Assigned to Arm(s): HC toolkit intervention students
B: Arm Label: New Moves Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: New Moves | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: New Moves; Assigned to Arm(s): New Moves Intervention Group
C: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Active Video Games | Intervention Type: OTHER; Name: Active Video Games; Assigned to Arm(s): Intervention Group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: 6 months of healthy physical activity | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: 6 months of healthy physical activity; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Brief Summary: This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis (AD).


Options:
A: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo (for Dupilumab), Other: Topical Corticosteroid (TCS) | Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo (for Dupilumab), Other: Topical Corticosteroid (TCS) | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Other: Topical Corticosteroid (TCS) | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg q2w, Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Dupilumab 300 mg q2w, Placebo qw | Intervention Type: OTHER; Name: Topical Corticosteroid (TCS); Assigned to Arm(s): Dupilumab 300 mg q2w, Dupilumab 300 mg qw, Placebo qw
B: Arm Label: Apremilast 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Arm Label: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Arm Label: Placebo + Apremilast 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo | Arm Label: Placebo + Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast 40 mg, Placebo + Apremilast 40 mg | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast 30 mg, Placebo + Apremilast 30 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Apremilast 40 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Placebo + Apremilast 30 mg
C: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo (for Dupilumab) | Arm Label: Dupilumab 300 mg once weekly (qw); Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Arm Label: Dupilumab 300 mg every 2 weeks (q2w); Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg every 2 weeks (q2w), Dupilumab 300 mg once weekly (qw) | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Dupilumab 300 mg every 2 weeks (q2w), Placebo
D: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Other: Background treatment | Arm Label: Dupilumab 200 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Other: Background treatment | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 200 mg qw | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo qw | Intervention Type: OTHER; Name: Background treatment; Assigned to Arm(s): Dupilumab 200 mg qw, Placebo qw

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Brief Summary: This is a randomized, double-blind, placebo-controlled, parallel-group study to confirm the efficacy and safety of Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis (AD).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Dupilumab) | Arm Label: Dupilumab 300 mg every 2 weeks (q2w); Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo (for Dupilumab) | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg every 2 weeks (q2w), Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Dupilumab 300 mg every 2 weeks (q2w), Placebo
B: Arm Label: AN2728 Topical Ointment, 2%; Type: EXPERIMENTAL; Interventions: Drug: AN2728 Topical Ointment, 2% | Arm Label: Matching vehicle control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching vehicle control | Intervention Type: DRUG; Name: AN2728 Topical Ointment, 2%; Assigned to Arm(s): AN2728 Topical Ointment, 2% | Intervention Type: DRUG; Name: Matching vehicle control; Assigned to Arm(s): Matching vehicle control
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Tralokinumab Dose 1; Type: EXPERIMENTAL; Interventions: Biological: Tralokinumab Dose 1 | Arm Label: Tralokinumab Dose 2; Type: EXPERIMENTAL; Interventions: Biological: Tralokinumab Dose 2 | Arm Label: Tralokinumab Dose 3; Type: EXPERIMENTAL; Interventions: Biological: Tralokinumab Dose 3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Tralokinumab Dose 1; Assigned to Arm(s): Tralokinumab Dose 1 | Intervention Type: BIOLOGICAL; Name: Tralokinumab Dose 2; Assigned to Arm(s): Tralokinumab Dose 2 | Intervention Type: BIOLOGICAL; Name: Tralokinumab Dose 3; Assigned to Arm(s): Tralokinumab Dose 3
D: Intervention Type: BIOLOGICAL; Name: omalizumab; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Permanent Versus Delayed-absorbable Monofilament Suture for Vaginal Graft Attachment During Minimally-invasive Total Hysterectomy and Sacrocolpopexy: A Randomized Clinical Trial
Brief Summary: Primary Aim:

The primary aim of this randomized controlled trial (RCT) is to compare vaginal mesh and suture exposure rates in women undergoing robotic total hysterectomy and sacrocolpopexy with a light-weight polypropylene mesh (Upsylon™ y-mesh) using permanent (polytetrafluoroethylene, Gore-Tex) versus delayed absorbable monofilament (2-0 polydioxanone, PDS) sutures through 1-year.

Secondary Aims:

1. To compare the 1-year composite success rate (leading edge of prolapse is at or above the hymen and apex has descended less than 1/3 of the vaginal length, no subjective feeling of bulge; and no retreatment for pelvic organ prolapse (POP) or vaginal mesh exposure) of permanent versus delayed absorbable sutures for mesh graft attachment during robotic total hysterectomy and sacrocolpopexy.
2. To evaluate adverse outcomes in each group


Options:
A: Intervention Type: PROCEDURE; Name: sacral colpopexy; Assigned to Arm(s): N/A
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: robotic laparoscopic sacrocolpopexy | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laparoscopic Sacral Colpopexy | Intervention Type: PROCEDURE; Name: robotic laparoscopic sacrocolpopexy; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Laparoscopic Sacral Colpopexy; Assigned to Arm(s): 1
C: Arm Label: Gore-Tex permanent suture; Type: ACTIVE_COMPARATOR; Interventions: Other: Polytetrafluoroethylene | Arm Label: PDS delayed absorbable suture; Type: EXPERIMENTAL; Interventions: Other: Polydioxanone | Intervention Type: OTHER; Name: Polytetrafluoroethylene; Assigned to Arm(s): Gore-Tex permanent suture | Intervention Type: OTHER; Name: Polydioxanone; Assigned to Arm(s): PDS delayed absorbable suture
D: Arm Label: SSLF and PMT; Type: EXPERIMENTAL; Interventions: Procedure: SSLF, Behavioral: PMT | Arm Label: ULS and PMT; Type: EXPERIMENTAL; Interventions: Procedure: ULS, Behavioral: PMT | Arm Label: SSLF without PMT; Type: EXPERIMENTAL; Interventions: Procedure: SSLF | Arm Label: ULS without PMT; Type: EXPERIMENTAL; Interventions: Procedure: ULS | Intervention Type: PROCEDURE; Name: SSLF; Assigned to Arm(s): SSLF and PMT, SSLF without PMT | Intervention Type: PROCEDURE; Name: ULS; Assigned to Arm(s): ULS and PMT, ULS without PMT | Intervention Type: BEHAVIORAL; Name: PMT; Assigned to Arm(s): SSLF and PMT, ULS and PMT

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tranexamic Acid in Knee Joint Surgery - a Randomised Controlled Trial
Brief Summary: Total knee joint replacement surgery can lead to significant blood loss, which can affect recovery after surgery. Tranexamic acid (TXA) is a medication which stops the breakdown of blood clots and therefore prevents blood loss. The optimal use of TXA remains a point of debate. Growing interest in the topical application of TXA (directly into the surgical wound) has been suggested as an alternative way of administering TXA, and may demonstrate similar effectiveness as when it is given intravenously. Therefore, this multicentred, randomized controlled trial, aims to investigate the safety and effectiveness of both topical and intravenous administrations of TXA in total knee joint surgery. The investigators predict that both routes of administration will demonstrate similar results when compared to placebo.


Options:
A: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline (0.9% NaCl) | Arm Label: Topical; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid, Drug: Normal saline (0.9% NaCl) | Arm Label: Systemic; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid, Drug: Normal saline (0.9% NaCl) | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Systemic, Topical | Intervention Type: DRUG; Name: Normal saline (0.9% NaCl); Assigned to Arm(s): Control, Systemic, Topical
B: Arm Label: Vitagel; Type: EXPERIMENTAL; Interventions: Device: Vitagel | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Vitagel; Assigned to Arm(s): Vitagel
C: Arm Label: Peri-articular group; Type: EXPERIMENTAL; Interventions: Drug: Peri-articular tranexamic acid | Arm Label: Intravenous group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous tranexamic acid | Intervention Type: DRUG; Name: Peri-articular tranexamic acid; Assigned to Arm(s): Peri-articular group | Intervention Type: DRUG; Name: Intravenous tranexamic acid; Assigned to Arm(s): Intravenous group
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2

Answer: A